Dietary Interventions During Living Kidney Donations

NCT ID: NCT05709600

Last Updated: 2024-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-01

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Monocentre, non-randomized, non-blinded, open-label interventional study to identification of relevant changes in molecular biology in proteome, phosphoproteome, lipidome, epigenome and transcriptome in pretransplant kidney biopsy samples in patients preconditioned by different dietary regimes (fasting mimicking diet vs. ketogenic diet vs. dietary restriction of sulfur containing amino acids vs. control patients)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute kidney injury (AKI) is one of the most common disorders in hospitalized patients and the incidence of AKI is rapidly rising, especially among high-risk patients. In a meta-analysis including 49 million patients, AKI occurred in every fifth adult and in every third children suffering from an acute illness, defined as critical care with admission to the intensive care unit (ICU), cardiac surgery, trauma, heart failure or underlying disease within the field of haematology/oncology. AKI is associated with substantial mortality, even in non-ICU patients mortality ranges high between 10-20% and AKI severity is related to increased mortality. In addition, non-recovery of kidney function rates between 13-29% and progression to chronic kidney disease (CKD) requiring dialysis after AKI is common. Despite the considerable burden associated with AKI, effective therapeutic approaches, including prevention strategies, are currently lacking.

Since impaired cellular stress resistance contributes to AKI, preconditioning protocols that augment stress resistance such as caloric restriction (CR) are attractive strategies in the search for organprotection. CR protects from kidney damage in rodent models of AKI, induced by either ischemia-reperfusion injury or by injection of nephrotoxic cisplatin. However, the translation of this potential to the clinical setting has been hampered by both the limited understanding of the underlying mechanisms paired with the risk of malnourishment and significant comorbidity in the target patient population in terms of frailty, multi-morbidity or preoperative settings.

Based on more recent results regarding novel dietary regimens, three well-established targeted diets (a fasting mimicking diet, a ketogenic diet and the dietary restriction of sulfur-containing amino acids and the dietary restriction of branched chained amino acids), which already proved their safety and feasibility in both phase-II and I clinical trials, are promising novel targeted dietary strategies beyond CR.

Intermittent fasting with fasting mimicking diets enables the activation of cellular signal transduction similar to CR with high nourishment. Fasting mimicking diet efficiently protects from acute kidney injury in rodents. Human FMD (Prolon®) is a plant-derived diet to achieve fasting-like effects on serum levels of insulin growth factor-1 (IGF-1), insulin growth factor protein-1 (IGFP-1), glucose and ketone bodies, while providing both macro- und micronutrients. Intermitted fasting with fasting mimicking diets have extensively been studied in rodents. Additionally, phase-II and phase-I studies proofed safety, feasibility and favorable outcome in healthy volunteers and patients with autoimmune disorders or diabetes.

Ketogenic diets are high in fat and very low in carbohydrates and result in ketogenesis with the synthesis of ketone bodies, exceeding β-oxidation of fatty acids and anti-inflammation. Furthermore, ketogenic diets extend the lifespan in rodents with preserved physiological functions. Ketone bodies, such as β-hydroxybutyrate, suppress oxidative stress resulting in nephroprotection. Due to their additional neuroprotective effects, ketogenic diets have been in medical use in pharmacoresistant epilepsy proofing their feasibility and safety in humans. Moreover, ketogenic diets in women with ovarian and endometrial cancer revealed favorable effects on physical activity, perceived energy and food cravings. Considering that CR actually does induce ketogenesis due to feeding cycles, ketogenic diets are a key strategy that needs to be examined as a replacement for caloric restriction.

The amino acid methionine is the start codon in protein translation and is essential in the synthesis of the amino acid cysteine, which is also a precursor for glutathione and s adenosylmethionine, both needed in detoxification and methylation. Dietary restriction of these two sulfur-containing amino acids has been shown to be required for the beneficial effects of caloric restriction in a rodent model of liver damage. In addition, restriction in sulfur containing amino acids efficiently protects from acute kidney injury in rodents. Cysteine/methionine restriction activates the transsulfuration pathway resulting in the generation of hydrogen sulfide (H2S) and is associated with anti-inflammation, increased stress resistance, reduction of reactive oxygen species and alteration in lipid-metabolism. Sulfur containing amino acids are abundant in animal-derived protein, but also exist in certain vegetables, fruits and grains. A dietary restriction of sulfur containing amino acids can be achieved by a vegan-based diet without fish, meat, dairy products and certain plant-based foods as well as using specific formula diets Objective of the proof-of-principle, pilot-DILKID-trial is to decipher the underlying mediating mechanisms of different, well-established, dietary regimens as well as to prove their feasibility, tolerability and safety in nephrology patients. Additionally, the organprotective effects of those preoperative dietary interventions in terms of the transplant function in the kidney recipient will be analyzed. Inter-group differences on transcriptome, lipidome, metabolome, epigenome and (phospho-) proteome in the collected tissue (kidney, vessel and fat tissue), as well as in blood cells, plasma and serum will be compared between the different study arms.

In addition, the DILKID-trial aims to prove nephroprotective effects observed in rodent studies in humans and to correlate them with clinical surrogate parameters for kidney function. Another goal of our study consists in the identification of distinct metabolic pathways that are mediated by the dietary preconditioning strategies mentioned above and resulting in novel therapeutic approach protecting from AKI in nephrology patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Living-Kidney Donors

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Transplant Acute Kidney Injury Kidney Dietary Interventions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fasting mimicking diet

Human fasting mimicking diet (Prolon®) for five days prior to living kidney donation in donor: Day 1 of Prolon® supplies \~4600 kJ, day 2-5 provide \~3000kJ.

Group Type ACTIVE_COMPARATOR

Fasting mimicking diet

Intervention Type DIETARY_SUPPLEMENT

Intermittent fasting with human fasting mimicking diet (Prolon®) will be performed for five days prior to living kidney donation in the donor. Prolon® a plant-based diet designed to attain fasting-like effects while provide providing both macro- and micronutrient. Each participant will obtain Prolon® diet during the first visit and the diet will stored at the participant's home at room temperature. Additionally, the participant will receive a food plan for the exact consumption of the diet. Regular phone with a predefined standardized questionnaire will be used to determine each participant's well-being, as well as his or her dietary adherence. Furthermore, the participants will be asked to write down each consumed food items they are consuming in diet-book, which is handed to them during the first visit.

The participants are only allowed to consume water, coffee or tea without sugar simultaneously to the Prolon® diet.

Ketogenic diet

Isocaloric, ketogenic diet 7 days prior to living kidney donation in the kidney donor with below 5% of energy from carbohydrate (\<20g/day), approximately 15% from protein (\<100g/day) and 80% from fat (\>125g/day) without changes in caloric supply calculated by the Mifflin-St.Jeor formula achieved by the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany).

Group Type ACTIVE_COMPARATOR

Ketogenic diet

Intervention Type DIETARY_SUPPLEMENT

Isocaloric, ketogenic diet will be performed for seven days prior to living kidney donation in the donor.

The ketogenic diet is based on the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany). Main fat sources are plant oils including palm oil and sunflower oils. The formula diet is provided as a powder that has to be mixed with water before use. To avoid a shortage in protein uptake supplement formula diets K-AM and Fortimel® (both Nutricia Milupa GmbH, Erlangen, Germany) will be used additionally. Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan by the dietetics at the University Hospital of Cologne to ensure standardized food consumption

Dietary restriction of sulfur containing amino acids

Isocaloric, dietary restriction of sulfur containing amino acids in the donor without changes in caloric supply calculated by the Mifflin-St.Jeor formula achieved by the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany).

Group Type ACTIVE_COMPARATOR

Dietary restriction of sulfur containing amino acids

Intervention Type DIETARY_SUPPLEMENT

Isocaloric, dietary restriction of sulfur containing amino acids will be performed for seven days prior to living kidney donation in the donor.

A dietary restriction of sulfur containing amino acids without restriction in protein uptake will be achieved by following the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany). The formula diet is provided as a powder that has to be mixed with water before use. A minimum of methionine and cysteine uptake (10% of the common uptake per day) will be achieved by consuming individuial calculated amounts of the Fortimel® formula diet (Nutricia Milupa GmbH, Erlangen, Germany). To avoid a restriction in fat and energy uptake additionally the Calogen and Duocal formula diets (both Nutricia Milupa GmbH, Erlangen, Germany) will be used. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan to ensure standardized food consumption.

Control-Group

Healthy, low-fat, moderate protein and high carbohydrate diet in the donor as described in the current nutritional recommendations of the American Diabetes Association achieved by the Fortimel® diet (Nutricia Milupa GmbH, Erlangen, Germany)

Group Type ACTIVE_COMPARATOR

Control Group ( healthy, low-fat, moderate protein and high carbohydrate diet)

Intervention Type DIETARY_SUPPLEMENT

Participants in the control group will be instructed to adhere to a healthy, low-fat, moderate protein and high carbohydrate diet as described in current nutritional recommendations. The control diet will be based on the formula diet Fortimel® (Nutricia Milupa GmbH, Erlangen, Germany). Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fasting mimicking diet

Intermittent fasting with human fasting mimicking diet (Prolon®) will be performed for five days prior to living kidney donation in the donor. Prolon® a plant-based diet designed to attain fasting-like effects while provide providing both macro- and micronutrient. Each participant will obtain Prolon® diet during the first visit and the diet will stored at the participant's home at room temperature. Additionally, the participant will receive a food plan for the exact consumption of the diet. Regular phone with a predefined standardized questionnaire will be used to determine each participant's well-being, as well as his or her dietary adherence. Furthermore, the participants will be asked to write down each consumed food items they are consuming in diet-book, which is handed to them during the first visit.

The participants are only allowed to consume water, coffee or tea without sugar simultaneously to the Prolon® diet.

Intervention Type DIETARY_SUPPLEMENT

Ketogenic diet

Isocaloric, ketogenic diet will be performed for seven days prior to living kidney donation in the donor.

The ketogenic diet is based on the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany). Main fat sources are plant oils including palm oil and sunflower oils. The formula diet is provided as a powder that has to be mixed with water before use. To avoid a shortage in protein uptake supplement formula diets K-AM and Fortimel® (both Nutricia Milupa GmbH, Erlangen, Germany) will be used additionally. Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan by the dietetics at the University Hospital of Cologne to ensure standardized food consumption

Intervention Type DIETARY_SUPPLEMENT

Dietary restriction of sulfur containing amino acids

Isocaloric, dietary restriction of sulfur containing amino acids will be performed for seven days prior to living kidney donation in the donor.

A dietary restriction of sulfur containing amino acids without restriction in protein uptake will be achieved by following the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany). The formula diet is provided as a powder that has to be mixed with water before use. A minimum of methionine and cysteine uptake (10% of the common uptake per day) will be achieved by consuming individuial calculated amounts of the Fortimel® formula diet (Nutricia Milupa GmbH, Erlangen, Germany). To avoid a restriction in fat and energy uptake additionally the Calogen and Duocal formula diets (both Nutricia Milupa GmbH, Erlangen, Germany) will be used. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan to ensure standardized food consumption.

Intervention Type DIETARY_SUPPLEMENT

Control Group ( healthy, low-fat, moderate protein and high carbohydrate diet)

Participants in the control group will be instructed to adhere to a healthy, low-fat, moderate protein and high carbohydrate diet as described in current nutritional recommendations. The control diet will be based on the formula diet Fortimel® (Nutricia Milupa GmbH, Erlangen, Germany). Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients \> 18 years of age
* Planed living kidney transplantation (both donor and recipient are eligible)
* Written informed consent

Exclusion Criteria

* Vegetarian lifestyle
* Body-Mass-Index (BMI) \< 18.5 kg/m2
* Calorie-reduced diet within the preceding four weeks
* Underlying wasting syndrome
* Contraindication for enteral nutrition
* Known allergy to or intolerance of the ingredients of the diet used
* Pregnancy
* Breastfeeding
* Absence of safe contraceptive measures or non-occurrence of menopause (in women)
* Participation in other interventional trials
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Cologne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Roman Müller

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roman-Ulrich Müller, Prof. MD

Role: PRINCIPAL_INVESTIGATOR

Department II of Internal Medicine, University Hospital of Cologne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department II of Internal Medicine, Center for Molecular Medicine Cologne (CMMC), University Hospital of Cologne

Cologne, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Felix Köhler, MD

Role: CONTACT

Phone: +49 221 478 97222

Email: [email protected]

Roman-Ulrich Müller, Prof. MD

Role: CONTACT

Phone: +49 221 478 97222

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Felix Köhler, MD

Role: primary

Roman-Ulrich Müller, Prof. MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

V1.1-25052022

Identifier Type: -

Identifier Source: org_study_id